Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Treatment Protocol of ruxolitinib in hydroxyurea-resistant or intolerant polycythemia vera
2014-001309-42Phase 3Completed
- Sponsor
- Novartis
- Start
- Aug 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ruxolitinib in polycythemia vera (PV), sponsored by Novartis. Primary endpoints: Safety (all adverse events), Grade 3 and 4 adverse events and 3 more. Started Aug 2014; status: completed.
02
Drugs
03
Conditions
polycythemia vera (PV)
Beyond the preview
Go deeper on 2014-001309-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001309-42.